Bring On the Orphans: Aegis Capital’s Raghuram Selvaraju Lays Out a Winning Biotech Strategy

The Life Sciences Report: Ram, it’s hard to imagine a situation where orphan drugs wouldn’t be reimbursed, because the needs are so great and the optics would be very bad for both payers and . . . → Read More: Bring On the Orphans: Aegis Capital’s Raghuram Selvaraju Lays Out a Winning Biotech Strategy Similar Articles: Pfizer Inc (NYSE:PFE) – French biotech Cellectis surges as Pfizer signs cancer drug deal Market Update: Texas Instruments Inc (NASDAQ:TXN) – Sales of digital cinema projectors with award-winning DLP Cinema® technology surpass 100,000-screen milestone Being Selective in Biotech: Carol Werther